臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 51651820 線上人數 : 943 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"lu l c"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 71-80 / 144 (共15頁)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-07-03T03:33:48Z	Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study	Lu L.-C.; PEI-JER CHEN; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L.
臺大學術典藏	2021-03-19T01:54:20Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	TSUNG-HAO LIU; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-19T01:54:20Z	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment	Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; TSUNG-HAO LIU; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-19T01:54:19Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; TSUNG-HAO LIU; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-19T01:54:19Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; TSUNG-HAO LIU; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-18T02:02:23Z	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment	Lu L.-C.;Lee Y.-H.;Chang C.-J.;Chia-Tung Shun;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; CHIA-TUNG SHUN; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-09T05:18:33Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-02-25T07:00:58Z	Solving the deficit of cancer pain management skills by education programs	YU-YUN SHAO; Lin W.-Y.; Lin C.-P.; Lu L.-C.; Hsu C.-H.

顯示項目 71-80 / 144 (共15頁)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每頁顯示[10|25|50]項目